Zacks Investment Research upgraded shares of Aimmune Therapeutics (NASDAQ:AIMT) from a hold rating to a buy rating in a research report report published on Thursday morning, Zacks.com reports. They currently have $22.00 target price on the biotechnology company’s stock.
According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “
AIMT has been the subject of several other reports. Cantor Fitzgerald reiterated a buy rating on shares of Aimmune Therapeutics in a research report on Thursday, April 11th. Credit Suisse Group initiated coverage on Aimmune Therapeutics in a research note on Tuesday, May 21st. They issued an outperform rating and a $30.00 price target on the stock. Wedbush decreased their target price on Aimmune Therapeutics from $80.00 to $76.00 and set an outperform rating on the stock in a research note on Tuesday, March 19th. Finally, BidaskClub lowered Aimmune Therapeutics from a hold rating to a sell rating in a research report on Thursday, April 11th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $46.43.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.94) by $0.07. Equities research analysts predict that Aimmune Therapeutics will post -3.77 earnings per share for the current fiscal year.
Hedge funds have recently bought and sold shares of the business. Marshall Wace North America L.P. acquired a new position in Aimmune Therapeutics during the first quarter worth $32,000. FMR LLC lifted its position in shares of Aimmune Therapeutics by 30.3% during the first quarter. FMR LLC now owns 2,734,583 shares of the biotechnology company’s stock valued at $61,117,000 after purchasing an additional 635,362 shares in the last quarter. Kore Private Wealth LLC bought a new position in shares of Aimmune Therapeutics during the first quarter valued at about $55,000. RMB Capital Management LLC increased its holdings in Aimmune Therapeutics by 96.1% during the first quarter. RMB Capital Management LLC now owns 94,004 shares of the biotechnology company’s stock worth $2,101,000 after buying an additional 46,064 shares during the last quarter. Finally, Opaleye Management Inc. increased its holdings in Aimmune Therapeutics by 10.0% during the first quarter. Opaleye Management Inc. now owns 165,000 shares of the biotechnology company’s stock worth $3,688,000 after buying an additional 15,000 shares during the last quarter. 76.13% of the stock is owned by hedge funds and other institutional investors.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.